 The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to determine a recommended Phase 2 dose RP2D for further development of this combination in subjects with untreated advanced pancreatic cancer. 